Alamo Medical Research

Alamo Medical Research is a premier clinical research site located in San Antonio, Texas, specializing in Phase II through Phase IV clinical trials for the pharmaceutical and biotechnology industries. The organization is widely recognized for its expertise in metabolic and liver diseases, particularly nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. Founded by Dr. Michael Almaleh, the site has established a reputation for high patient enrollment and high-quality data collection in complex therapeutic areas. In July 2021, Alamo Medical Research was acquired by Velocity Clinical Research, a leading integrated site organization. Following the acquisition, the site continues to operate as part of Velocity's global network, supporting drug development for major global sponsors.